MY208219A - Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof - Google Patents

Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof

Info

Publication number
MY208219A
MY208219A MYPI2019003407A MYPI2019003407A MY208219A MY 208219 A MY208219 A MY 208219A MY PI2019003407 A MYPI2019003407 A MY PI2019003407A MY PI2019003407 A MYPI2019003407 A MY PI2019003407A MY 208219 A MY208219 A MY 208219A
Authority
MY
Malaysia
Prior art keywords
adm
antibody
adrenomedullin
scaffold
congestion
Prior art date
Application number
MYPI2019003407A
Other languages
English (en)
Inventor
Adriaan Voors
Original Assignee
Adrenomed Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16206305.1A external-priority patent/EP3339324A1/en
Application filed by Adrenomed Ag filed Critical Adrenomed Ag
Publication of MY208219A publication Critical patent/MY208219A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MYPI2019003407A 2016-12-16 2017-12-18 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof MY208219A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16204847 2016-12-16
EP16206305.1A EP3339324A1 (en) 2016-12-22 2016-12-22 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
EP17197176 2017-10-18
PCT/EP2017/083311 WO2018109228A1 (en) 2016-12-16 2017-12-18 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof

Publications (1)

Publication Number Publication Date
MY208219A true MY208219A (en) 2025-04-24

Family

ID=61148166

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019003407A MY208219A (en) 2016-12-16 2017-12-18 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof

Country Status (13)

Country Link
US (2) US20200299372A1 (enExample)
EP (1) EP3555130A1 (enExample)
JP (3) JP7727371B2 (enExample)
KR (3) KR20250084231A (enExample)
CN (2) CN110167962B (enExample)
AU (2) AU2017375049B2 (enExample)
BR (1) BR112019011713A2 (enExample)
CA (1) CA3046850A1 (enExample)
IL (2) IL322765A (enExample)
MX (1) MX2019007107A (enExample)
MY (1) MY208219A (enExample)
RU (2) RU2021135712A (enExample)
WO (1) WO2018109228A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119215164A (zh) * 2017-09-25 2024-12-31 艾德里诺医药公司 用于治疗或预防疾病症状的抗肾上腺髓质素（adm）结合剂
EP3871689A1 (en) * 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
CA3168978A1 (en) * 2020-02-27 2021-09-02 Andreas Bergmann Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
EP4121771A1 (en) * 2020-03-16 2023-01-25 AdrenoMed AG Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
CN119072492A (zh) 2022-03-15 2024-12-03 艾德里诺医药公司 抗肾上腺髓质素（adm）抗体或抗adm抗体片段的稳定水性制剂

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
CN1628126A (zh) 2001-08-30 2005-06-15 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
JP2007523844A (ja) 2003-04-25 2007-08-23 ジェノバ・リミテッド 心臓血管障害において減少する分泌ポリペプチド種
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
WO2006027147A2 (en) 2004-09-09 2006-03-16 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
AU2005287557B2 (en) 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
US20110301332A1 (en) * 2008-07-01 2011-12-08 Cephalon Australia (Vic) Pty Ltd. Anti-pamp therapeutic antibodies
CN102272148A (zh) 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
EP2470556B1 (en) 2009-08-27 2018-05-30 Covagen AG Il-17 binding compounds and medical uses thereof
JP5667207B2 (ja) 2009-12-14 2015-02-12 シル プロテインズ ゲーエムベーハーＳｃｉｌ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ リガンドへの結合能を有するヘテロ多量体修飾ユビキチンタンパク質の同定方法
TR201906295T4 (tr) 2010-06-08 2019-05-21 Astrazeneca Ab IL-4 R alfaya bağlanan gözyaşı lipokalini muteinleri.
BR112012032389A2 (pt) * 2010-06-18 2016-10-25 Brahms Gmbh biomarcadores para a previsão de câncer incidente
JP6336911B2 (ja) * 2011-11-16 2018-06-06 シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング アドレノメジュリンアッセイおよび成熟アドレノメジュリンの測定方法
PT2780371T (pt) 2011-11-16 2019-01-30 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica
JP6321544B2 (ja) 2011-11-16 2018-05-09 アドレノメト アクチェンゲゼルシャフト 慢性若しくは急性疾患又は急性病態に罹患している患者の死亡リスクを低減するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
PT2780370T (pt) * 2011-11-16 2019-10-30 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento anticorpo anti-adm ou estrutura de anticorpo anti-adm não ig para utilização na terapia de uma doença aguda ou condição aguda de um paciente para estabilizar a circulação
SG10201801919QA (en) 2011-11-16 2018-04-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
WO2013072512A1 (en) * 2011-11-16 2013-05-23 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy

Also Published As

Publication number Publication date
KR20240033285A (ko) 2024-03-12
CN110167962B (zh) 2024-06-07
RU2021135712A (ru) 2021-12-30
CA3046850A1 (en) 2018-06-21
IL267282A (en) 2019-08-29
BR112019011713A2 (pt) 2019-10-15
AU2017375049A1 (en) 2019-06-13
RU2762059C2 (ru) 2021-12-15
JP2020503013A (ja) 2020-01-30
CN118767128A (zh) 2024-10-15
KR20190120174A (ko) 2019-10-23
JP2023052614A (ja) 2023-04-11
AU2025202983A1 (en) 2025-05-22
US20200299372A1 (en) 2020-09-24
MX2019007107A (es) 2019-10-21
US20220041703A1 (en) 2022-02-10
RU2019122135A (ru) 2021-01-18
JP7727371B2 (ja) 2025-08-21
WO2018109228A1 (en) 2018-06-21
JP2024170454A (ja) 2024-12-10
CN110167962A (zh) 2019-08-23
IL322765A (en) 2025-10-01
RU2019122135A3 (enExample) 2021-02-10
EP3555130A1 (en) 2019-10-23
KR20250084231A (ko) 2025-06-10
AU2017375049B2 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
HUE067888T2 (hu) Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
MA43343A (fr) Méthodes de conditionnement de patients pour la thérapie cellulaire t
NZ720949A (en) Methods and compositions for treating aging-associated conditions
MX378273B (es) Compuestos activos hacia bromodominios.
MY193661A (en) Anti-tim3 antibodies and methods of use
MX370480B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
EA201692436A1 (ru) Медицинское применение
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
DK3700529T3 (da) Ny kombination af aktive midler til behandling af progressive fibroserende interstitielle lungesygdomme (pf-ild)
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
MY208219A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
IL283096A (en) Medical tool positioning devices, systems, and methods of use and manufacture
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
CY1122784T1 (el) Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1
HK1257415A1 (zh) 结合到抗n-甲基-d-天冬氨酸(nmda)受体抗体的结合区的抗体或抗体片段或非ig支架
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
HUE051948T2 (hu) Protokollok és eljárások sclerosis multiplex kezelésére ofatumumab alkalmazásával
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
HUE066487T2 (hu) Regorafenib és nivolumab kombinációja rák kezelésére